Taihe Weiye Biotechnology

Chengdu Taihe Weiye Biotechnology Co., Ltd, a Chinese developer of protected amino acids drugs, has reportedly secured nearly RMB 300 million (USD 42 million) in a Series A+ financing round, following its RMB 200 million (USD 28 million) Series A funding in August this year. The latest round was co-led…